GenMark Diagnostics, Inc. (NASDAQ:GNMK) reported Q2 2017 earnings this Morning, coming in at ($0.37) per share, missing Wall Street’s estimates of ($0.32) per Share. Revenue for the quarter came in at $12.36 million missing the streets estimates of $12.44 million
Analyst Coverage For GenMark Diagnostics, Inc. (NASDAQ:GNMK)
These are 4 Buy Ratings .
The current consensus rating for GenMark Diagnostics, Inc. (NASDAQ:GNMK) is Buy (Score: 3.00) with a consensus target price of $17.00 , a potential (43.70% upside)Recent Insider Trading for GenMark Diagnostics, Inc. (NASDAQ:GNMK)
- On 6/2/2017 Michael Gleeson, SVP, sold 357 with an average share price of $12.89 per share and the total transaction amounting to $4,601.73.
- On 5/19/2017 Hany Massarany, Insider, sold 8,239 with an average share price of $12.89 per share and the total transaction amounting to $106,200.71.
- On 5/19/2017 Michael Gleeson, SVP, sold 1,916 with an average share price of $12.89 per share and the total transaction amounting to $24,697.24.
- On 5/19/2017 Scott Mendel, CFO, sold 2,135 with an average share price of $12.89 per share and the total transaction amounting to $27,520.15.
- On 5/16/2017 Scott Mendel, CFO, sold 1,268 with an average share price of $13.43 per share and the total transaction amounting to $17,029.24.
- On 5/2/2017 Eric Stier, SVP, sold 362 with an average share price of $13.34 per share and the total transaction amounting to $4,829.08.
Recent Trading for GenMark Diagnostics, Inc. (NASDAQ:GNMK) Shares of GenMark Diagnostics, Inc. closed the previous trading session at 9.90 down -1.93 -16.31% with 184,689 shares trading hands.